KS

Kseniya Simpson

Principal at Hatteras Venture Partners

Raleigh-Durham-Chapel Hill Area

Overview 

Kseniya Simpson is a Principal at Hatteras Venture Partners, with a background that includes roles as an Associate, Senior Analyst, and Analyst within the company. She has served on the boards of multiple organizations, including Ten63 Therapeutics, Aer Therapeutics, Inc., Code Biotherapeutics, and more, showcasing her leadership and strategic capabilities in the biotech sector. With a PhD from Yale School of Medicine and a BS from the University of Chicago, Kseniya Simpson's career highlights include her current role as Principal at Hatteras Venture Partners and her involvement in various boards, demonstrating her expertise in the biotech industry and her ability to drive strategic decision-making.

Work Experience 

HV

Hatteras Venture Partners

  • Principal

    2024 - Current

  • Associate

    2022 - 2024

  • Senior Analyst

    2021 - 2022

  • Analyst

    2019 - 2020

Venture Capital Multiplier Fund is a venture capital firm

hatterasvp.com
TT

Trefoil Therapeutics

  • Board Director

    2025

  • Board Observer

    2022 - 2025

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.

Raised $85,775,048.00 from Hatteras Venture Partners, Bios Partners, Correlation Ventures, Hatteras Venture Partners, Aju IB Investment, InFocus Capital Partners, Access Biotechnology and ExSight Ventures.

trefoiltherapeutics.com
TT

Ten63 Therapeutics

  • Board Observer

    2023

AT

Aer Therapeutics, Inc.

  • Board Observer

    2022

Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.

Raised $36,000,000.00 from Hatteras Venture Partners, Canaan Partners and OrbiMed.

aertherapeutics.com
CB

Code Biotherapeutics

  • Board Observer

    2022

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

Raised $85,000,000.00 from UPMC Enterprises, Amgen Ventures, CureDuchenne Ventures, New Enterprise Associates, 4BIO Capital, UCB Ventures, Takeda Ventures, JDRF T1D Fund, Northpond Ventures and Hatteras Venture Partners.

codebiotx.com
NC

North Carolina Biosciences Organization (NCBIO)

  • Board of Directors

    2021

VN

Vigil Neuroscience

  • Board Observer

    2020 - 2022

    NASDAQ: VIGL IPO: 01/2022

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Raised $180,000,000.00 from Sanofi.

vigilneuro.com
TI

Triangle Insights Group, LLC

  • Strategy Consultant

    2017 - 2018

  • Associate Strategy Consultant

    2016 - 2017

Uo

University of North Carolina at Chapel Hill

  • Postdoctoral Fellow

    2015 - 2015

    Laboratory of Dr. Joseph DeSimone (currently Professor of Translational Medicine and Chemical Engineering at Stanford University)

YV

Yale Ventures

  • Licensing Intern

    2013 - 2015

Education 

Articles About Kseniya

Relevant Websites